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A general introduction on treatment goals and treatment strategies in diabetes mellitus is de-
scribed in chapter 1. The aim of this thesis was to reach a greater understanding in treatment 
goals and effectiveness of treatment strategies on glycemic control in people with T2DM in 
daily practice. Secondly, the evaluation of an intervention to improve patient involvement was 
described. Finally, the development of an intervention to optimize diabetes treatment was de-
scribed. 
In the first part of this thesis (chapters 2 – 4), we focused on the treatment of T2DM in the real 
world. 
In chapter 2 we investigated the time to insulin initiation in people with T2DM not responding to 
oral glucose lowering agents and we evaluated long term outcomes, including glycaemic control, 
micro vascular complications and mortality. Our study demonstrated that two-third of the people 
with T2DM initiated insulin during follow up. The time to insulin varied from 1.2 years (range 0.3-
3.1) in patients with HbA1c levels consistently ≥ 53 mmol/mol (7.0%) to 5.4 years (range 3.0-7.5) 
in patients with fluctuating HbA1c levels around 7.0%. Longer diabetes duration (HR1.04 95% 
CI 1.03-1.05) and lower age (HR1.00 95% CI 0.99-1.00) at baseline were associated with a shorter 
time to initiation. More insulin initiators had retinopathy compared to people with T2DM that 
remained on oral glucose lowering agents during follow up.
In chapter 3 we described subgroups with distinct HbA1c trajectories in insulin users. We identi-
fied four HbA1c trajectories. Most people were classified in a stable HbA1c trajectory of around 57 
mmol/mol (7.4%) (88.7%). Only 24.4% of the people were ‘on-target’ to insulin, this was associated 
with lower HbA1c levels and higher age at the start of insulin treatment. Initiating insulin earlier 
improves the likelihood of achieving and sustaining glycemic control.
In chapter 4 we described subgroups with distinct HbA1c trajectories of the overall T2DM popula-
tion. Four subgroups with distinct HbA1c trajectories were identified. More than 90% reached and 
maintained good glycemic control (subgroup one and two). Persons within the two subgroups 
that showed a more unfavorable course of glycemic control, were younger, had higher HbA1c 
levels and a longer diabetes duration at baseline.
The second part of this thesis focused on co-morbidities in T2DM management (chapters 5,6). 
In chapter 5 we investigated subgroups with distinct trajectories of systolic blood pressure in the 
overall T2M population. Four subgroups with distinct SBP trajectories were identified. The largest 
subgroup (85.6%) showed adequate SBP control (at or around 140 mmHg) over time. The second 
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subgroup (5.6%) were hypertensive in the first years, responded slowly to BP management and 
eventually reached SBP control. The third subgroup (3.4%) showed deteriorating hypertension 
during the first four years, then showed insufficient response to BP management. The fourth sub-
group (5.4%) showed deteriorating hypertension over time. People with T2DM within subgroups 
2-4 were significantly older, comprised more women, used more antihypertensive medication 
and had a higher prevalence of retinopathy, microalbuminuria and CVD mortality. 
In chapter 6 we described the use of antidepressants, anxiolytics and hypnotics in people with 
T2DM and determined the socio-demographic characteristics and T2DM medication associ-
ated with use. We demonstrated that from the 7,016 people with T2DM, 500 people (7.1%) used 
antidepressants only, 456 people (6.5%) used anxiolytics and/or hypnotics only and 254 people 
(3.6%) used a combination. Users were more often female, non-Caucasian and lower educated 
compared to non-users. Users of anxiolytics and/or hypnotics were older, had a higher BMI, and 
more co-morbidities compared to non-users. Moreover, antidepressant users more often used 
insulin (27.2% vs. 21.5%). Finally, glycaemic control did not differ between users and non-users 
(51-52 mmol/mol vs. 52 mmol/mol).
In the last part of this thesis, we described two interventions to improve patient involvement in 
their T2DM treatment and evaluate treatment strategies(chapter 7,8). 
The study described in chapter 7 evaluated the feasibility of a web-based guided insulin self-
titrationprogram in people with T2DM. The most important lesson to be learned was to investi-
gate the potential barriers that PCPs may face before implementing an e-health program in order 
to a) try to embed and tailor a program to the PCP organisation b) decide on not to implement 
if doubts exist about embedding or need is lacking. Other option is to change the setting of 
implementation towards a setting facilitating embedding or towards a setting with an existing 
need for e-health application.
The study described in chapter 8 described the development of a tool for clinical medication 
review to facilitate and support the periodic review of (older) patients’ medication by community 
pharmacists and primary care physicians. A structured, comprehensive and practical tool to as-
sist pharmacists and general practitioners to perform clinical medication review including a list 
of potential drug-related problems in older patients with chronic disease, as well as a script for 
structured patient interviews, was developed.
Chapter 9 provides a general discussion based on main findings and future perspectives.
